Selamectin

Pet parasitic infection is a common disease in the global companion animal medical field. Infections caused by ectoparasites such as Sarcoptes scabiei, fleas and Otodectes cynotis will not only cause skin inflammation and anemia in animals, but also may埋下 hidden dangers for the transmission of zoonotic diseases. Selamectin is a semi-synthetic antiparasitic API of avermectin class. It enhances the permeability of parasite nerve cell membranes to chloride ions, inhibits nerve conduction, and ultimately leads to paralysis and death of parasites. It is one of the core raw materials for current topical anthelmintic preparations for dogs and cats. Meanwhile, it can also be used for parasite prevention and control of some fur economic animals, and is a representative component with both broad spectrum and safety in the field of veterinary anthelmintics.

The global market size of veterinary antiparasitic drugs exceeded US$11 billion in 2023, among which avermectin drugs account for more than 35%. As a new generation of topical avermectin API, selamectin has maintained a compound annual growth rate of 8.2% in the past three years, which is significantly higher than the average growth rate of traditional veterinary anthelmintic APIs. At present, the global selamectin production capacity is mainly concentrated in China and Europe. Domestic enterprises, relying on their advantages in cost and technology, have occupied more than 60% of the global API supply share. With the continuous increase of the global pet ownership rate, the demand from the downstream preparation end is expected to maintain a stable growth trend.

The original research enterprise of selamectin is Pfizer, and the original trade name is Revolution. The expiration date of its core compound patent in the United States was 2016, and the core patent in the European Union expired in 2017. The main dosage form approved by the original research is topical drops, and common specifications include 0.25ml, 0.5ml, 1.0ml, 2.0ml and other different specifications, which are suitable for dogs and cats of different weights. This original preparation has been included in the FDA Reference Listed Drug Catalog, and is also included in the *Catalog of Chemical Drugs* of China. Up to now, a number of enterprises have obtained A-status registration for their selamectin APIs on China's CDE API Registration Platform, and multiple selamectin topical drop preparations have been approved for marketing in China. (Data as of September 2024, please refer to the official CDE website for the latest information)

CATO provides a full set of selamectin impurity reference standards. Most products are in stock, and in-stock products ordered before 16:00 will be shipped on the same day. They are compliant with multiple regulations such as Chinese Pharmacopoeia and FDA, and can fully meet the impurity reference substance needs of API enterprises in the whole process of process R&D, quality research, registration and declaration, etc., helping enterprises efficiently promote the compliant launch of products.